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ABSTRACT 
Interest in amorphous pharmaceutical systems is steadily 
growing over the last 10 years.  The amorphous state is critical in 
determining the solid state, physical and chemical properties of 
many pharmaceutical dosage forms. The main reason of the growing 
interest toward amorphous materials is the need to improve the 
bioavailability of drugs with poor aqueous solubility. Many drugs 
exist in crystalline solid form due to reasons of stability and ease of 
handling during the various stages of drug development. Conversion 
of the crystalline to amorphous form may occur during various 
pharmaceutical processes.  This could change the dissolution rate 
and transport characteristics of the drug. The current focus of 
research in this area is to understand the origins of amorphous 
forms. The various thermodynamic phenomena such as glass 
transition, fragility, molecular mobility, devitrification kinetics, 
molecular level chemical interactions, solubility and stability are 
critically discussed. The aim of this review is to understand the 
recent development in the area of amorphous state and to address 
the current challenges faced by pharmaceutical formulation and 
process development scientists and thus is mandatory to anticipate 
future developments. 
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INTRODUCTION 
Amorphous forms, by definition, are the 
distinct class of solids, separated from the more 
common and well-known crystalline solids. At 
the molecular level, they lack the three-
dimensional long-range order.  Instead, their 
molecules are randomly arranged in space and 
the interactions between neighboring molecules 
are not repeated (Morris et al., 2001). Their 
structure can be thought of as being similar to 
that of a frozen liquid with the thermal 
fluctuations present in a liquid frozen out, 
leaving only "static" structural disorder (Elliot et 
al., 1986). Amorphous state is characterized by 
randomly arranged molecules, of which the 
motions are kinetically frozen, at least on 
experimental time scales. A little provocation 
by different stressors can accelerate the 
mobility of molecules and facilitate the 
achievement of most stable and ordered 
crystalline states. These issues gain greater 
importance during pharmaceutical manufac-
turing processes, wherein a solid experiences 
the variable extent of stress (Gupta et al., 2004). 
Solubility of a given solid is a sum of crystal 
packing energy, cavitation and solvation energy. 
Amorphous state exists due to the absence of 
an ordered crystal lattice which requires 
minimal energy thus providing the maximal 
solubility advantage as compared to the 
crystalline and hydrated forms of a drug as 
shown in figure 1. (Gupta et al., 2004). 
Crystalline and amorphous states of a 
solid exhibit altered molecular interactions 
(Tang et al., 2002) which may pose as energy 
barriers for phase transformations. These 
structural changes depend on adjustment in the 
nearest neighbor relationships, including 
parameters such as intermolecular distances and 
patterns in hydrogen bonding (Brittain 2002).  
The process can be envisioned as decrease in 
configurational entropy with a simultaneous 
increase in the number of molecules 
constituting cooperatively rearranging regions, 
favoring a gain in molecular order. Interest in 
amorphous pharmaceutical systems has been 
steadily growing over the last 10 years.  But the 
current interest has been raised by major 
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developments like growing attention to 
pharmaceutical solids in general, especially 
polymorphs and solvates   (Zhou et al., 2002; 
Bhugra et al., 2006) and a revived interest in the 
science of glasses and the glass transition 
(Angell 1996). 
 
 
 
Figure 1. a) Amorphous arrangement; b) 
Crystalline arrangement 
 
Screening for amorphous materials  
In recent years, several amorphous active 
pharmaceutical ingredients (APIs) have been 
marketed as drug products. Some of them 
which include are Accolate (zafirlukast), Ceftin  
(cefuroxime axetil), and Accupril  (quinapril 
hydrochloride). Lilly's Humulin L contains both 
amorphous and crystalline insulin to provide 
immediate and long-term effects. An 
amorphous material can be substantially more 
soluble than the corresponding crystalline 
material, as much as 1600 times more soluble 
according to a recent publication (Hancock, 
2000). In some cases, this increased solubility 
leads to enhanced bioavailability. Because of 
these potential benefits, solid form screening 
should encompass a search for both crystalline 
and amorphous forms. This application note 
suggests a strategy for finding the best 
amorphous form early in drug development, 
using small amounts of material, with the 
overall goal of reducing the time to launch. 
Three main steps involved in the development 
strategy are assessment of the API solubility, 
and the second is screening for amorphous 
forms and the third step is determination of the 
stability of amorphous forms (Byrn et al., 1995). 
The goal of a micro amorphous screen is to 
prepare amorphous forms on the micro scale 
using a variety of methods. Solid State 
Chemical Information (SSCI), a division of 
Aptuit provides comprehensive cGMP solid 
state chemistry research and analytical services 
to the pharmaceutical industry. SSCI help with 
many different aspects of solid form screening. 
 Methods used at SSCI include flash 
evaporation, lyophilization, and quench cooling 
of the melt. Such procedures are performed at 
scales that provide about 0.1 to 5 mg of each 
sample. If larger amounts of material are 
available, grinding experiments at ambient or 
liquid nitrogen temperatures are carried out. 
Samples are analyzed by x-ray powder 
diffraction (XRPD), followed by other 
techniques as needed. Estimation of the 
solubility and stability of amorphous material 
prepared in the screen can also be 
accomplished using the small, initially formed 
samples. SSCI uses several technologies for 
carrying out microscale reactions. One is SSCI's 
patented capillary crystallization technology, 
which provides very high supersaturation levels 
through simple evaporation experiments, 
establishing conditions conducive to the 
formation of solid forms ranging from the 
most stable to higher free energy solids to very 
unstable forms. Amorphous materials are not 
as thermodynamically stable as their crystalline 
counterparts, and thus are commonly found 
using the capillary method. Samples generated 
in capillaries can be analyzed in situ by XRPD, 
optical microscopy, Raman spectroscopy, and 
differential scanning calorimetry. The small 
amount of sample necessary for generation and 
analysis of a solid in a capillary (0.05 to 1 mg) 
makes this technology ideal for micro screening 
(Chyall et al., 2002). 
 
Methods of forming an amorphous 
sample 
Amorphous substances can be classified 
as “strong” and “fragile” glass formers. Due to 
some kinetic and thermodynamic reasons, 
preparation of amorphous solids is easy and 
direct for good glass formers and difficult for 
poor glass formers i.e fragile glass formers 
(Lian, 2001). 
 
Separation / precipitation of solid from 
liquid  
The methods included using this principle is 
as follows. 
Spray drying  
In recent years, drug substances with 
poor aqueous solubility have become 
increasingly common, presenting formulators 
with a considerable number of extra challenges. 
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One emerging technology that has gained 
something of a reputation for offering a 
relatively straightforward solution to these 
problems is the solid dispersion technique. This 
involves molecular or colloidal dispersions of 
amorphous compounds, which are scientifically 
proven to dissolve more easily than crystalline 
forms. The evidence suggests that formulations 
containing amorphous active pharmaceutical 
ingredients (APIs) present enormous potential 
in overcoming problems of limited 
bioavailability of poorly-soluble APIs. 
Scientists have in the past been 
somewhat reluctant to adopt this principle, 
largely because of concerns over stability and 
issues relating to limited shelf life. But more 
recently, it has been shown that properly 
formulated solid dispersions actually offer long-
term stability, thus removing a key barrier to 
evaluating the technology. They can either be 
prepared by melt extrusion or spray-drying, but 
the advantages of the latter allow formulators 
to choose from a wide selection of polymers, 
solvents and adjuvants. In recent Contract 
Pharma analysis, spray-drying was pinpointed 
as an "excellent" manufacturing option when 
working with temperature-sensitive solutions. 
This is because the spray-drying process 
involves relatively low temperatures and only 
limited contact with the hot processing gas.  
Generally speaking, the use of spray-
drying to manufacture solid dispersions is a 
relatively simple process. First of all, the drug 
substance is dissolved in a solvent system 
together with a polymer dispersant system and 
any other necessary adjuvants to form the 
spray-drying feed solution that will be used. 
Next, this is pumped into the top of the spray-
dryer, along with nitrogen, or another heated 
gas, before being atomised into fine droplets. 
As the droplets descend through the drying 
chamber, the solvent is quickly removed, 
leaving a dry power with distinct properties. 
This powder can then be collected in a cyclone 
and secondarily dried to remove residual 
solvents in accordance with guidelines from the 
International Conference on Harmonisation 
(ICH).  
"One of the advantages of spray-drying 
is its ability to control powder characteristics 
which can have a tremendous impact on 
secondary formulation and manufacturing of 
tablets or capsules. This is where expertise and 
a strong understanding of the fundamentals of 
spray-drying can define success or failure of a 
solid dispersion,". Careful selection of spray-
drying equipment and parameters, such as 
inlet/outlet temperatures and feed solution 
variables, allow various powder characteristics, 
from particle size and distribution to 
dispersability and flow can all be efficiently 
controlled.  
Particularly important is the evaluation 
of inlet, outlet and condenser temperatures, 
which allows the engineer to design highly-
efficient and reproducible spray-drying 
processes. Mr Ross noted that parameters such 
as bulk density, flowability and residual solvent 
levels are all highly impacted by the 
temperatures. "For example, spray-drying at 
lower outlet temperatures will produce a 
powder with greater bulk density but a higher 
residual solvent level. Although most spray-
dried solid dispersions will require some level 
of secondary drying, residual solvent levels of 
the powder must be evaluated as they can have 
a significant impact on the short term, and 
thereby long-term physical stability," he added. 
Finally, it is important for evaluation to be 
conducted to establish the extent to which 
outlet temperatures impact the physical stability 
of the amorphous powder, as well as other 
properties that may influence secondary dosage 
development. 
Spray drying often results in physical 
transformation i.e., it leads to conversion of a 
crystalline phase to an amorphous state, 
because the amorphous state is metastable with 
respect to the crystalline form. Spray-drying 
was performed using a laboratory scale spray 
dryer under the standard set of conditions like 
drug solution concentration, inlet and outlet 
temperature, feed rate, drying air flow rate and 
atomization air pressure (Jeong-Soo, 2008). The 
amorphous materials being in a thermo-
dynamically metastable state, are susceptible to 
reconversion to the crystalline state and affects 
many physicochemical characterization of the 
drug (Jacob, 2011).   
 
Solidification from the melt 
Although this technique is not used in 
the large scale production of pharmaceutical 
products, this technique is often employed on 
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the laboratory scale as a first approach to 
prepare the amorphous phase of a compound. 
The advanced techniques for preparing 
amorphous solids span the range of quenching 
rates. These techniques are not  fundamentally 
different from those used for preparing 
crystalline solids (Fig.1). The  point is simply 
that care is taken to quench fast enough to 
form the glass rather  than slow enough to 
form the crystal.  For materials with very high 
glass-forming tendency, the melt can be 
allowed to cool slowly by simply turning off the 
furnace or by bringing it down in a 
programmed manner (Fig1.1a). Typical cooling 
rates are in the range from 10-4 to 10-1° K/sec.  
  Somewhat faster rates are needed to 
quench a glass such as amorphous selenium, an 
elemental glass composed of long-chain 
polymeric molecules. Using an ice-water bath 
to quench modest volumes of the melt, yields 
rates in the range 101- 102° K/sec (Fig1.1b). Se 
glass can be prepared by this method. This 
metallic glass has a glass-forming tendency high 
enough to allow it to be prepared in bulk form, 
rather than the thin-film form characteristic of 
other metallic glasses. There are other 
techniques also for the melt-quenching 
methods developed specifically for metallic 
glasses. These methods are collectively called 
splat-quenching techniques (Fig1.1c), and 
achieve T values in the range 105-108°K/sec 
(Zallen, 1998). 
 
 
 
Figure 2. a) slow cooling; b) moderate 
quenching; c) rapid splat quenching; d) 
condensation from the gas phase. 
Freeze drying  
In a freeze drying process, rapid freezing 
favors the formation of an amorphous solute, 
whereas introducing an annealing step may 
promote crystallization (Pikal, 1994). Lyophili-
zation is highly limiting in its scope when 
applied to organic small molecules with poor 
aqueous solubility. Although lyophilization can 
be performed with organic solvents, it is not a 
preferred technique since complete removal of 
solvent from the system may be challenging 
(Nagapudi et al., 2008). 
 
Mechanical disruption of an ordered 
structure 
Milling 
It is a Process that introduce mechanical 
or chemical stress (e.g., grinding, milling and 
wet granulation) which can render crystalline 
materials fully or partially amorphous. 
 
Dehydration 
Dehydration of crystalline hydrates has 
been demonstrated as a feasible and „„gentle‟‟ 
route to the amorphous state of organic solids. 
Saleki Gerhardt et al., showed that heating the 
crystalline raffinose  pentahydrate at 60°C in 
vacuum converts the material to an amorphous 
form (Saleki-Gerhardt et al., 1995). 
Preparation methods are found to 
influence the solubility, as well as physical and 
chemical stability of amorphous drugs. Zhang et 
al., (2009) investigated physical and chemical 
stability of the Quench-cooled amorphous 
simvastatin and cryo-milled amorphous 
simvastatin and revealed that the solubility of 
amorphous forms prepared by both methods 
was enhanced compared to the crystalline form. 
The amorphous substances have many useful 
properties like higher solubility, dissolution 
rate, and better compression characteristics 
than corresponding crystals. The amorphous 
solids are generally less stable physically                
and chemically than corresponding crystals 
(Vogel et al., 1921).  
 
Characterization of amorphous materials 
The key to understanding the properties 
of the amorphous state is recognized by the 
fact that molecules in this state can exhibit 
significant molecular motion over timescales of 
pharmaceutical interest both above and below 
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the glass transition temperature (Tg). The glass 
transition temperature is where an amorphous 
substance changes from a super-cooled liquid 
with relatively low viscosity to an unstable glass 
with much greater viscosity. Motion in the 
form of translational and rotational diffusion, 
which is essential for any physical or chemical 
process, can generally be described in terms of 
temperature, viscosity, and molecular size. It 
can occur in seconds at and above Tg to 
months or years below Tg. In some cases 
amorphous materials can be produced by 
mixing solids so that molecular dispersions 
result. The dispersions will have properties 
distinct from those of the individual compon-
ents. Molecular dispersions are important in 
pharmaceutical situations such as: stability in 
sugar-protein lyophilized and spray dried 
products, dissolution of orally administered 
drug-polymer dispersions, crystallization in 
transdermal patches, mechanical characteristics 
of plasticizer-polymer film coating systems and 
process-induced drug excipient interactions. 
There are a variety of physical techniques 
utilized for characterizing amorphous solids. X-
ray powder diffraction measurements are used 
to confirm the crystalline or amorphous nature 
of the starting materials. As shown in figure 3, 
it is used to determine if any change in their 
form occurred as a result of their testing. 
 
 
 
Figure 3. X-ray diffraction patterns for 
powdered amorphous and crystalline samples 
of an experimental drug substance (Hancock et 
al., 2002). 
 
Differential scanning calorimetry (DSC) 
is the most widely used thermal analytical 
technique applied to the characterization of 
amorphous solid dispersions. It measures the 
rate of heat flow to measure the heat of 
transition. As all transitions in materials involve  
flow of heat (into the sample in endothermic 
events and out of the sample for exothermic 
events) DSC is the universal detector for 
measuring the wide variety of transitions in 
pharmaceutical materials (Jared et al., 2011). 
Other important techniques include Scanning 
electron microscopy, Isothermal calorimetry, 
Dielectric analysis, Dynamic Mechanical 
Analysis, Dilatometry and thermal stimulating 
current. 
The structure of amorphous solids is 
usually described as possessing crystals like 
short range molecular rearrangement, but 
lacking long range order. If crystallization is 
avoided, many liquids of pharmaceutical 
relevance vitrify at a temperature (Tg) approxi-
mately 2/3 to 4/5 of the crystalline melting 
point, Tm. Modulated DSC and can be used to 
separate reversing and non-reversing compo-
nents at a glass transition (e.g., in a spray dried 
lactose), a beneficial utility in the assignment of 
glass transitions that are weak or overlap with 
other thermal events. Apart from quench 
cooling, a melt miscible impurity may be 
introduced to inhibit crystallization. Crystalliza-
tion of carbohydrates and derivatives, which are 
common pharmaceutical excipients, presents a 
special challenge. Xylitol, for instance, is 
crystallized initially as a more stable polymorph, 
with the metastable form being impossible to 
make again. 
 
Properties of amorphous materials 
Some of the important properties that 
include are Amorphous particles appear dark 
under polarized light microscope, typically 
exhibit a  significant initial increase in aqueous     
solubility  and dissolution rate relative to the 
crystalline  material, True density of the 
amorphous form  is  5–20% less than the 
crystalline  form, X-rays are randomly diffract-
ted by amorphous powders resulting in a broad 
halo for the diffraction pattern (Figure. 4) 
(Crocker et al., 1997) and water vapor is sorbed 
by amorphous samples in large and non-
stoichiometric amountsrelative to crystalline 
samples (Zografi et al., 1994). The tendency            
for amorphous materials to sorb significant 
amounts of water vapor from their surround-
dings (Figure 4) can give markedly reduced 
chemical and physical stability relative to the 
crystalline form of the material.     
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Figure 4. Water vapor sorption isotherm for 
crystalline and amorphous samples of 
indomethacin ( ) Amorphous; ( ) crystalline 
(Andronis et al., 1997) 
 
Limitations of amorphous systems such 
as physical instability and higher chemical 
reactivity, act as a hurdle in their extensive 
commercialization. Thereby, it is important to 
understand the molecular and thermodynamic 
properties that contribute to the solubility and 
stability of amorphous drugs. Thermodynami-
cally, the amorphous form is characterized by 
presence of „excess‟ enthalpy, specific volume, 
entropy and free energy. The properties of 
these characterized materials are as follows. 
 
Glass transition temperature 
Glass transition temperature is the 
characteristic property of amorphous materials. 
There has been a constant debate over glass 
transition being a kinetic or a thermodynamic 
phenomenon. The thermodynamic viewpoint 
suggests that as Tg is associated with a change 
in the derivative of extensive thermodynamic 
properties such as volume, enthalpy, entropy 
and heat capacity, the glass transition is a 
second-order thermodynamic phase transition. 
The Tg is also thought to be a “thermodynamic 
necessity” to prevent the “entropy crisis” of the 
non crystalline state. In contrast, the kinetic 
view  point   explains   the  observed  structural  
 
 
changes as the consequence of a dynamic 
transition in the relaxation of the super cooled 
liquid, which is not associated with any abrupt 
changes in thermodynamic parameter. The 
glass transition event in kinetic terms is based 
on relaxation times. The “structural relaxation 
time” is defined as the time taken by the 
molecule to diffuse from the centre of its 
vibration to another centre across 
intermolecular distance. Tg is defined as the 
temperature at which mean relaxation time (t) 
changes by two to three orders of magnitude 
and equals the time of observation (t0). Tg is a 
kinetic parameter and is observed to vary with 
temperature scanning rate and thermal history 
(Weuts et al., 2003). 
 
Fragility 
Amorphous substances can be classified 
as “strong” and “fragile” glass formers based 
on the temperature dependence of mean 
relaxation time (or viscosity) above Tg depicted 
by the Angell‟s plot. Strong glass formers show 
an Arrhenius type relationship with activation 
energy independent of temperature. At the 
molecular level, strong glass formers exhibit an 
open network structure, with a built-in 
resistance to structural change with increasing 
temperature. Thus strong glasses exhibit small 
change in heat capacity at Tg. On the other 
hand, fragile glass formers show a non linear 
dependence upon temperature. Materials with 
fragile behavior indicate a greater tendency to 
devitrify over the shelf life. The temperature 
dependence of molecular mobility/viscosity 
can be determined by the Vogel-Tammann-
Fulcher equation. The term used to describe 
the sensitivity of a material to physical aging is 
“fragility”. Fragility may be measured by DSC. 
The enthalpic fragility parameter (Robertson et 
al., 2000) is defined as 
 
mΔh = -(d log βc)/(d(Tf,ref/Tf) 
 
mΔh  is the fragility parameter, 
βc   is the perior cooling rate, 
Tf  is the fictive temperature measured in 
heating  
Tf,ref is the reference fictive temperature 
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Molecular mobility  
Molecular mobility of amorphous 
pharmaceuticals is a key factor in determining 
their stability, reactivity, and physicochemical 
properties. Crystallization is a process that 
involves two separate but interdependent steps: 
nucleation followed by crystal growth. It is 
important to note that both these steps require 
diffusion or rearrangement of molecules either 
to form agregates of molecules leading to stable 
nuclei or to attach to a growing crystal face, 
thus one of the key attributes that govern the 
physical stability of an amorphous glass or 
supercooled liquid is molecular mobility 
(Hancock et al., 1995) . Likewise, chemical 
reactivity also depends on some level of 
molecular mobility (Yoshioka et al., 2007). In 
addition to the excess thermodynamic 
properties described previously, the amorphous 
state also has excess volume or “free volume” 
in relation to the equilibrium crystalline state, 
and even though the amorphous glass exhibits 
solid-like behavior below Tg, there is sufficient 
free volume that molecular motions leading to 
molecular rearrangements can occur (Hancock 
et al., 1997). Over time these molecular 
rearrangements can manifest as either 
relaxation of the amorphous glass to a lower 
free energy state or formation of stable nuclei, 
leading to devitrification of the glass to a more 
stable crystalline state. There are numerous 
reports describing crystallization of amorphous 
materials following storage at temperatures 
below Tg (Alig et al., 1997; Bhugra et al., 2008; 
Yoshioka et al., 2004) and nucleation has been 
reported at temperatures as low as 55°C below 
Tg (Hancock et al., 1995). Consequently there is 
intense interest in being able to predict physical 
stability by understanding and measuring 
molecular mobility; however, as will be 
discussed, this is an extremely challenging 
undertaking. This is in part due to the strong 
dependence of molecular mobility on 
temperature, as discussed in more detail below. 
 
Temperature dependence of relaxation 
process 
As the temperature of an undercooled 
liquid approaches the glass transition (Tg), the 
viscosity increases, the free volume in the 
system decreases, and the time for a molecule 
to diffuse an interparticulate distance or the 
structural relaxation time increases. Both 
structural relaxation and viscosity of a material 
exhibit strong temperature dependences  
(Figure 5), with relaxation times on the order of 
100s at Tg compared to hours and days at 
temperatures below Tg, while viscosity can vary 
from > 1012 Pas below Tg to 10-4 Pas at the 
melting temperature (Hancock et al., 1999).   
 
 
 
Figure 5. Temperature dependence of average 
molecular relaxation times (Hancock, 2002) 
 
Devitrification kinetics  
The rate and mechanism of 
devitrification of amorphous solid is material 
specific and dependent on environmental 
conditions (temperature, pressure, and/or 
humidity) encountered during processing of 
solid dosage forms (Gupta et al., 2005).  
 
Effect of humidity 
The higher hygroscopicity of the 
amorphous system is usually higher in 
comparison to the crystalline drug which 
further enhance devitrification. Typically, 
crystalline materials adsorb vapors in smaller 
quantities at their surface. In contrast, 
amorphous systems absorb vapors in relatively 
large amounts (even up to 100 % by weight) 
(Yoshioka et al., 2007).  It has been shown that 
even a small amount of amorphous material, 
embedded within a largely crystalline matrix, 
preferentially absorbs water vapor. This 
amplifies the local water content and a 
corresponding plasticization of the amorphous 
structure (Ahlneck et al., 1990; Gupta et al., 
2004). Thus, relative humidity is an important 
factor influencing the solid-state properties of 
glassy systems. Water acts as a potential 
plasticizer that increases the free volume 
conducive to greater molecular motions 
favoring devitrification. Storage of amorphous 
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celecoxib at 25°C and a range of humidity 
conditions (0%, 35%, 60%, and 80% RH) are 
found to result in complete devitrification. 
Storage at high humidities resulted in 100% 
crystallization in <3 days, whereas 0% RH 
could sustain the crystallization by allowing 
80% crystallization in 75 days. Thus, exposure 
to humidity favored crystallization of 
amorphous solid. A rapid rate of devitrification 
can lead to quick loss of solubility advantage. 
 
Effect of processing stress on devitri-
fication of amorphous solid 
The disordered molecular arrangement 
in amorphous form contributes excess 
properties (ie, enthalpy, entropy, and free 
energy) (Yu, 2001) which act as a constant 
driving force for loss of energy and regain of 
order by reverting to the thermodynamically 
stable crystalline form. The dissipation of this 
energy could be enhanced to a variable extent 
in the presence of different stress-inducers. 
Manufacturing of a solid dosage form involves 
various unit operations, like size reduction 
(mechanical and thermal stress), drying 
(thermal stress), blending (mechanical stress), 
granulation (mechanical and humidity stress), 
compression (mechanical and thermal stress), 
coating (thermal and humidity stress), and so 
forth, which can provide sufficient inputs for 
reducing the energy gap between the metastable 
amorphous and stable crystalline form. The 
behavior of amorphous solid in the presence of 
these processing stresses would allow for 
adoption of suitable measures in the designing 
of amorphous systems that can be 
advantageously used. To eliminate the small 
crystalline fractions retained during preparation 
of amorphous solid, inclusion of high Tg 
additives can provide benefit in terms of 
reduction of molecular motions within the 
experimental time frame. This goal can be 
achieved with the use of poly(vinyl 
pyrrolidone), (Dmitri, et al., 2007)  which 
provides stability to amorphous solid during 
storage, as well as dissolution. 
 
Molecular interactions in crystalline and 
amorphous state  
The amorphous state differs from the 
crystalline state in the molecular level 
arrangements. The low molecular weight 
organics such as pharmaceutical materials show 
extensive hydrogen bonding, complex 
molecular geometry and conformational 
flexibility, which together define the ease of 
glass formation and its subsequent stability. 
Spectroscopic techniques that are used to study 
inter and intra molecular hydrogen bonding, 
structural shape, steric hindrance and inter-
conversion between conformational isomers, 
can explain the glass formation and their 
physical stability. These differences in 
interactions manifest as different macroscopic 
properties of the crystalline and amorphous 
state (Yu, 2001). 
 
Thermodynamics of amorphous materials 
Amorphous systems have been known 
to demonstrate an „excess‟ of thermodynamic 
properties (enthalpy, entropy, and free energy) 
relative to their crystalline counterparts. On the 
one hand, these „excess‟ properties bestow 
enhanced solubility, improved bioavailability 
and better compressibility, however, on the 
other hand, they are responsible for their 
physical instability by way of devitrification. 
Compared to the crystalline form of a drug, the 
amorphous form is in a state of higher energy. 
This is due to the fact that the amorphous state 
possesses excess thermodynamic properties 
such as enthalpy, entropy and Gibbs free 
energy. The relationship of the thermodynamic 
properties and temperature for the amorphous 
and crystalline state is shown in figure 1 As a 
liquid melt of a crystal is cooled rapidly, 
recrystallisation may be prevented and the slope 
of the equilibrium liquid line may be followed 
below the melting temperature, Tm, resulting in 
a gradual decrease of thermodynamic 
properties below Tm. This is the super-cooled 
liquid state, in which viscosity is low (typically 
around 10−3 − 1012 Pa s) and mobility of the 
molecules is high and they are able to follow 
any further decrease of temperature to attain 
equilibrium conditions. However, upon further 
cooling, at the glass transition temperature (Tg), 
the molecules cannot follow the decrease in 
temperature any longer and the system 
solidifies, falling out of equilibrium. This is 
represented by the change of the slope in 
Figure 1.5. Below the Tg, the system is in the 
glassy state, exhibiting high viscosities of > 1012 
Pas. 
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Figure 6. Thermodynamic relationship of 
crystalline and amorphous state as a function of 
temperature (Hancock et al., 1997) 
 
If the Tg did not occur and the system 
remained in equilibrium throughout the cooling 
process, the super-cooled liquid line would be 
followed (now as an equilibrium glass) and it 
would intersect the crystal line at the 
Kauzmann temperature, TK. Below the TK, the 
amorphous system would have lower entropy 
and enthalpy than the crystalline state, which 
presents a violation of the laws of 
thermodynamics. Therefore, the occurrence of 
the Tg has two implications for amorphous 
systems. Firstly glasses are in a non-equilibrium 
state and equilibrium thermodynamics cannot 
be applied below that temperature and secondly 
the physico-chemical properties of amorphous 
systems above and below the Tg are different. 
During storage, it is often observed that the 
amorphous state reduces its excess enthalpy 
and entropy without recrystallising. This is 
called “relaxation” as the amorphous state 
relaxes towards a lower energetic state, still 
remaining in the amorphous form. The real 
glass relaxes asymptotically towards the 
equilibrium glassy state. This relaxation 
behaviour can be seen as an indication that 
below the Tg mobility is low, but still existent. 
The higher energetic state is beneficial in terms 
of improving the solubility of a compound. 
However, it is detrimental to the physical 
stability (Hilden et al., 2004; Yu 2001). Due to 
the enhanced thermodynamic properties of the 
amorphous state compared to the crystalline 
state, recrystallisation provides a means of 
reducing this excess free energy but in DO Ing 
so, the solubility advantages are negated. 
Crystallisation is a result of a nucleation 
process, where stable nuclei are created, 
followed by crystal growth. The recrystallisation 
of an amorphous form is governed by the same 
factors as the crystallization from a melt 
(Hancock et al., 1997) and therefore the 
crystallisation processes have been described on 
the basis of the classical nucleation theory 
(CNT) for homogenous nucleation (Schmelzer 
200841). Nucleation is a process which involves 
the overcoming of a potential barrier and is 
first described by Gibbs (Longley, 1948). The 
change of Gibbs free energy (ΔG), due to the 
formation of a cluster of the new phase 
(crystal) is given by equation 1: 
ΔG = ΔGV + ΔGS …………………(1) 
ΔGS is the change in surface free energy 
(in J mol−1) and ΔGV is the volume free energy 
change (in J mol−1). The value of ΔGS is 
associated with the formation of the cluster and 
represents a positive quantity. 
The value of ΔGV is associated with the 
phase transition of liquid to solid and 
represents a negative quantity (Rodrıguez-
Hornedo et al., 1999). According to the CNT, 
when nucleation occurs, clusters grow and 
decay until a stable nucleus is formed. After a 
cluster of a critical size has been formed, it will 
grow in size and hence recrystallisation of the 
amorphous form takes place. Nucleation and 
crystal growth are not solely governed by 
thermodynamics but also require individual 
molecules to move via diffusion. This kinetic 
proportion of the recrystallisation effect is 
usually considered as the molecular mobility or 
its reciprocal, the relaxation time. It has long 
been suggested that molecules exhibit sufficient 
mobility only at temperatures close to or above 
the Tg, and storage at temperatures below Tg 
would ensure physical stability. It has however 
been found that nucleation and crystal growth 
also occur at temperatures well below the Tg, 
however, the relative rate may be much slower 
than in the temperature region above the Tg  
(Bhugra et al., 2008; Yoshioka,1994). Recrystal-
lisation should therefore be influenced by 
thermodynamic (such as enthalpy, entropy and 
Gibbs free energy) and kinetic parameters  
(such as mobility). A commonality of the 
thermody-namic and kinetic parameters is the 
involve-ment of the configurational entropy 
(Sconf) which is the difference in entropy 
between the amorphous and the crystalline 
state. 
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Thermodynamic involvement of Sconf 
The desired properties of the amorphous 
state (higher solubility and dissolution rate 
compared to the crystalline form) have been 
attributed, at least in part, to an increase in 
thermodynamic properties, e.g., free energy, 
entropy and enthalpy. This change in free 
energy is regarded as a driving factor for 
recrystallization. The larger the difference in 
free energy between the amorphous and 
crystalline state the more thermodynamically 
favorable the situation will be upon 
recrystallisation. The difference in Gibbs free 
energy between the amorphous and the 
crystalline states can be calculated using 
enthalpic and entropic values for the 
amorphous and crystalline state as tated below: 
Gconf = Hconf(T)+ Sconf(T)      ………(2)    
The term “configurational” denotes the 
difference between the amorphous and the 
crystalline state and the parameters Hconf and 
Sconf may be calculated from their relationship 
with the heat capacity. 
                                        
 
 
 
Hconf is the configurational enthalpy (in 
Jmol−1), Sconf the configurational entropy (in 
Jmol−1K−1), ΔHm the melting enthalpy of the 
crystal (in Jmol−1) and ΔSm the melting entropy 
of the crystal (in Jmol−1K−1). The melting 
entropy can be obtained from the following 
relationship:  
                       
 
The configurational thermodynamic values give 
an indication of the relationship between the 
amorphous state and the crystalline state of             
a   compound.  The  larger  the  co  figurational  
values are the greater are the differences 
between the crystalline and the amorphous 
states. The configurational heat capacity, Cpconf , 
required to calculate the configurational 
properties, is the difference between the 
amorphous and the crystalline heat capacities. 
Cpconf is not identical to ΔCp, which denotes the 
heat capacity change of the amorphous state at 
Tg as shown in figure 7. Below the Tg the heat 
capacity values of the glass and the crystal may 
be similar, however, the heat capacities are not 
identical, therefore, Cpconf is never zero. After 
passing through the Tg the Cpconf of an 
amorphous compound may increase or 
decrease with temperature or follow a specific 
temperature dependence, depending on the 
properties of the material (Hodge 1996; 
Privalko 198045, 46). The temperature 
dependence of the configurational heat capacity 
above Tg has been described by the hyperbolic 
relation presented below: 
 
 
 
Figure 7. Heat capacity difference (ΔCp) and 
configurational heat capacity (Cpconf) of 
indomethacin 
 
Kinetic involvement of Sconf 
The amorphous state not only possesses 
higher thermodynamic properties compared to 
the crystalline state, it also shows enhanced 
molecular mobility (Shamblin et al., 1999) and 
this is considered an important factor for the 
subsequent physical and chemical instabilities 
(Tombari et al., 2008). Crystal nuclei formation, 
the first step of the recrystallisation process,        
is  a  result  of  the  localized  faster  mobility of  
molecules (Williams et al., 1970) and 
degradation reactions such as hydrolysis or 
protein degradation have been attributed to 
increased molecular mobility within the 
amorphous state (Yoshioka et al., 2007). 
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Molecular mobility has therefore been the topic 
of numerous investigations, however, due to 
the complex nature of the amorphous state and 
the still poorly understood relaxation 
properties, to date no single equation can be 
used to estimate the relaxation time of the 
amorphous state. Among those generally used 
are the Kohlrausch–Williams–Watts equation 
(KWW) (Williams et al., 1970), the Adam- 
Gibbs equation (AG) (Adam et al., 1950)              
and the Vogel–Tamman–Fulcher equation 
(VTF) (Fulcher 1925, 1965; Tammann et al., 
1926; Vogel, 1921).  These equations all show 
advantages and disadvantages as they address 
different issues, but the most commonly used 
equation to estimate the molecular mobility for 
the temperature range below the Tg is the AG. 
The governing thought of the AG equation is 
that a liquid consists of regions that rearrange 
themselves in units, the so-called cooperatively 
rearranging regions (CRR). Upon cooling from 
the super-cooled liquid state, these CRR 
become progressively larger. The size of the 
CRR is determined by the difference in the 
configurational entropy, Sconf , of the liquid 
which varies with temperature. When the 
temperature is high, the Sconf is large and the 
size of the CRR is small. Upon cooling, the 
Sconf decreases and in return the size of                 
the CRR increases. In the AG theory,                         
this increasing co-operativity is believed to be 
due to a loss of configurational entropy, which 
enables the calculation of molecular mobility. 
 
   
             
with relaxation time below Tg (in s),  pre-
exponential parameter (lifetime of the atomic 
vibrations, 10-14 s), activation energy of 
cooperative rearrangement (J mol−1), s*conf 
entropy of smallest cooperative molecular 
region (J mol−1 K−1), kB Boltzmann constant 
(1.38 JK−1) and Sconf(T) configurational entropy 
at temperature T (J mol−1 K−1). 
Equation 9 simplifies to the following 
expression if the properties of the glass forming 
liquid (Δµ and s*conf ) are considered constant: 
C is a constant. 
By applying equation 10 it has to be 
considered that the entropic contributions are 
entirely due to Sconf and any other influence 
(e.g.,vibrational entropy) is neglected (Pjohari, 
2001),. As a result, Sconf has a direct influence 
on the relaxation time and therefore on 
molecular mobility. As a glass relaxes 
isothermally, it reduces a portion of its excess 
entropy which in return leads to an increase of 
relaxation time. The molecular mobility of an 
amorphous state therefore is not only 
temperature dependent but also time 
dependent. A convenient way to express the 
temperature and time dependence of the 
molecular mobility is to introduce the fictive 
temperature, Tf   (Figure 8). 
 
 
 
Figure 8. T is the isothermal relaxation 
temperature, Tf is the fictive temperature and  
Tg is the glass transition temperature 
(Kawakami  et al., 2005). 
 
Relationship of enthalpy and tempera-
ture for an amorphous system 
A real glass is not in equilibrium, 
therefore applying thermodynamic principles 
proves challenging. However, thermodynamics 
can be estimated by relating the real glass to    
the theoretical equilibrium glass at the          
same temperature. The fictive temperature             
is defined as the temperature at which the 
system under investigation has the same   
thermodynamic properties as its equilibrium 
state    at    that   temperature    and   that  time.  
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The configurational entro-py (Vogel, 1921) can 
therefore be descrybed by  
with Sg conf 
configurational entropy of the real glass (in J 
mol−1 K−1), Seconf configurational entropy of the 
equilibrium super-cooled liquid (in J mol−1 K−1) 
and Tf fictive temperature (in K). The fictive 
temperature is a convenient way of describing 
the temperature and time dependence of Sconf 
for real glasses and enables calculation of 
molecular mobility in these systems. Through a 
number of rearrangements and substitutions of 
Sconf in equation 10 (Hilden et al., 2004) the AG 
equation 12 can be written as: 
 
…………(12) 
D is the dimensionless Angell‟s strength 
parameter and T0 is the temperature of zero, 
Sconf (in K). The relaxation time  may 
therefore be expressed by the fictive 
temperature which contains the contributions 
from the configurational entropy. 
 
Involvement of Sconf in solubility predi-
ction 
Amorphous compounds show a higher 
apparent solubility than their crystalline 
counterparts (Chiou et al., 1970) due to their 
higher energetic state and the disordered 
structure that does not require the crystal lattice 
to be broken upon dissolution. According to 
studies (Parks et al., 1928) the theoretical 
solubility ratio of the 
amorphous and crystalline form at a given 
temperature can be described through the free 
energy difference between the two forms 
(Parks et al., 1928; Parks et al., 1934).  
 
 
Gas constant R = 8:314 J mol−1 K−1 
The value of Gconf can be calculated as 
presented in equation 2, via Cpconf and hence 
Sconf. This approach has already been success-
fully applied for estimating the solubility 
differences between different crystalline poly-
morphs (Aguiar et al., 1967; Grant et al., 1990). 
In the reported literature, experimental 
solubility increases of up to 10 fold have been 
reported (Hancock et al., 2000) for amorphous 
systems, which in return can increase the 
bioavailability of a poorly soluble compound 
considerably. However, for amorphous 
compounds the calculated solubility may 
increase by up to 1,600 fold (Chawla et al., 
2007). This potential increase usually is not 
observed in vitro and the estimated values are 
significantly smaller. This is partly due to the 
fact that the amorphous state is far from 
equilibrium which poses difficulties in 
determining their equilibrium thermodynamic 
properties and partly due to the tendency of the 
amorphous state to revert back to the 
crystalline state upon exposure to solvents such 
as water or biorelevant media (Grant et al., 
1990). It is also observed that the amorphous 
state does not recrystallise to its original 
crystalline state but may crystallise to a 
different, potentially less soluble, polymorph 
(Savolainen et al., 2009). This is not trivial and 
can pose challenges during development of 
drug formulations. Despite their inaccurate 
values for absolute solubility, the estimated 
solubility ratios are a useful tool for estimating 
the theoretical maximal solubility and serve as 
an indication of the theoretical driving force for 
dissolution. These considerations regard the 
Sconf highlight the importance of this parameter 
in terms of amorphous stability and solubility 
which are the major factors of interest in 
pharmaceutics. 
 
Stability of amorphous solids  
The amorphous state, being a high-
energy state, is usually less stable than the 
corresponding crystalline form. Therefore, it is 
important to store the amorphous material 
under conditions that suppress its tendency to 
undergo unwanted physical changes (e.g., 
crystallization, aggregation of proteins) and also 
chemical degradation over the shelf life of the 
product (Shamblin et al., 1999). 
The main challenge in working with the 
amorphous form of drugs is their physical 
instability. In order to benefit from the 
advantages (enhanced solubility may lead to 
higher bioavailability) of the amorphous form, 
methods of stabilizing the amorphous state 
against recrystallization need to be found and 
optimized (Andronis et al., 1997; Hancock et al., 
1995; 2000).  
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Parameters used for the prediction of 
stability mean relaxation time constant 
(Ԏ ) 
 The molecular relaxation processes are 
typically non-exponential and are usually 
characterized using the empirical Kohlaursch-
William-Watts (KWW) equation. Determina-
tion of the relaxation process at different 
storage conditions to determine the relaxation 
or aging behaviour is a means to assess the 
“effective age” of an amorphous raw material 
(Chawla et al., 2009). In lieu of glass transition, 
molecular mobility has been quantified in terms 
of structural relaxation time measurements. 
Correlation between physical stability of the 
amorphous phase and relaxation time has been 
explored in large number of publications (Zhou 
et al., 2002; Yoshioka et al., 2001; Yoshioka et 
al., 2004). Structural relaxa-tion time can be 
determined in the time domain using methods 
like DSC and thermal activity monitor or in the 
frequency domain using methods like DES, 
SSNMR and TSDC (Carpentier et al., 2006).  
 
Relaxation time distribution parameter 
(β) 
β is a fitting parameter that represe-nts 
the breadth or skewness of the relaxa-tion time 
distribution. Using equation (5) the average 
relaxation time Ԏ at a temperature T can be 
calculated. Typically materials that have long 
relaxation times (in order of hundreds of days 
to years) at the storage temperature are said             
to be physically stable. Such measurements can 
be done for either AAPI (Amorphous              
Active Pharmaceutical Ingredient) or ASD 
(Amorphous Solid Dispersion) materials 
(Marsac et al., 2006; Marsac et al., 2008) 
Relaxation time measurements provide an 
estimate for the physical stability of amorphous 
materials using small amounts of material and 
as such are useful measurements to carry out 
while developing the amorphous phase as a 
preclinical candidate. These measure-ments are 
carried out in dry nitrogen atmos-phere (~ 0% 
RH) in DSC and consequently do not shed any 
light on the effect of moisture on crystalliza-
tion. It is well known that moisture acts as a 
plasticizer and reduces glass transition 
temperature and thereby can have a profound 
impact on glass transition and the dynamics 
associated with glass transition. 
Temperature characteristic parameters 
(enthalpy and entropy) and crystalliza-
tion   rate constant (k)   
The amorphous samples are annealed at 
various temperatures below glass transition 
temperaturefor different lengths of time. For 
each time period the enthalpic recovery is 
measured. From the enthalpic recovery the 
fraction of glass relaxed Ф(t) can be calculated 
using: 
   is the enthalpic 
recovery at time t and temperature T. is 
the maximum enthalpic recovery at the 
temperature T. can be calculated using: 
 (4) 
 is the heat capacity change across 
glass transition that is observed at the start of 
the experiment and Tg is the glass transition 
temperature.  Recent studies have been 
reported where crystal nucleation has been 
found to occur at temperatures well below the 
glass transition temperature. It is believed that 
at temperatures in the range of Tg-40o c, the 
beta relaxation is the dominant relaxation 
mechanism. As opposed to glass transition 
(alpha relaxation), the beta relaxation is 
associated with high frequency small length-
scale molecular motions. Examples of such 
localized motions include rotations of methyl 
groups and ring flips in benzene groups. Such 
motions well below Tg could lead to 
spontaneous formation of crystal nuclei thereby 
generating physical instability in the amorphous 
phase. Based on these observations it has been 
argued that, if the storage temperature is well 
below Tg, then beta relaxation process must be 
characterized (as it is the dominant relaxation 
process) to make meaningful inferences                 
of amorphous stability. The beta process can  
be directly observed and activation energies  
can be calculated when DES and TSDC 
techniques are used (Shmeis et al., 2004).                
If the activation barrier is high, then the 
probability   of   nucleation  is  considered  low.  
Recently Vyazovkin (Shmeis et al., 2004) have 
employed DSC to study the beta relaxation in 
indomethacin (Vyazovkin et al., 2007; 
Vyazovkin et al., 2006). In this study the beta 
relaxation manifests itself as an endothermic 
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peak below glass transition. By investigating the 
scanning rate dependence of the temperature 
location of beta transition, the authors are able 
to calculate the activation energy of the beta 
relaxation. Beta relaxation is an event associated 
with low heats and as such DSC may not be the 
best method to investigate it. The commonly 
used method of storing drugs at or below their 
Kauzmann temperature (Tk) [which is usually 
estimated to be 50 K below their glass 
transition temperature (Tg)] is governed by the 
principle that at sufficiently low temperatures, 
molecular mobility practically ceases. However, 
the „Tg–50 K rule of thumb‟ does not guarantee 
sufficient stability over the desired shelf-life, as 
recrystallization has been observed for a 
number of drugs at temperatures well below Tg. 
The factors governing recrystallization still are 
poorly understood, but thermodynamic and 
kinetic parameters are thought to influence 
stability. Kirsten A Graeser, et al., (2010) 
assessed the configurational  properties of 
some amorphous drugs to predict the physical 
stability using acetaminophen, cefuroxime 
axetil, donepezil HCl, fenofibrate, griseofulvin, 
ibuprofen, indomethacin, lacidipine, nifedipine, 
simvastatin, tolbutamide and troglitazone drugs 
and conc for the configurational entropy and 
hence the solubility ratios.n 
 
Stabilization of amorphous solids, 
The stabilization of amorphous solids is 
multifaceted which includes physical and 
chemical aspects: 
 
Physical aspects 
Stabilization of labile molecules  
  Freezing and drying are essential steps 
in the preparation of protein and peptide 
formulations (Pikal, 1994) and in the 
preservation of organisms (Crowe, et al., 1998). 
It has been observed that the peptides and 
organisms can be effectively protected against 
freezing and drying damages when they are co-
processed with certain excipients, typi cally 
carbohydrates and derivatives (sucrose, trehal- 
poly(vinylpyrrolidone) and poly(vinylpyrroli-
done- ose, mannitol, sorbitol, etc.) (Carpenter, 
1994; Sun et al., 1998) . 
 
 
Protection against crystallization of 
excipients 
It is generally accepted that in order to 
act as stabilizers, an excipient must mix 
homogeneously with the drug to be stabilized. 
However certain excipients (e.g., mannitol) 
have strong tendency to stabilizing crystallize, 
leading to phase separation and loss of 
stabilizing power. Crystallization can also lead 
to the formation of slow dissolving particles, 
causing slow reconstitution of parenteral 
products. 
 
Vitrification  
Vitrification based stabilization relies on 
immobilization and isolation of labile 
substances. In vitrification based stabilization 
strategies, Tg provides a concrete guide to the 
selection of stabilizers and storage 
temperatures. By eliminating plasticizers and 
introducing antiplasticizers one can increase Tg 
and reduces structural mobility. 
 
Chemical aspects 
The prevention of chemical degradation 
and microbial growth by the use of anti-
oxidants, pH, buffer and preservatives is very 
critical in pharmaceutical processing of 
amorphous solids. 
 
Prime approaches of stabilization  
Storge at Tg - 50K temperature conditions 
At temperature T0 or Tg-50K the 
molecular mobility is lowered and thus            
the reversion process is limited. This approach 
is less widely accepted as providing such 
temperature conditions during pharmaceutical 
processing, handling and storage is not  
feasible. 
 
Antiplasticization approach 
 When the amorphous drug is dispersed 
in a carrier (antiplastcizer) matrix which                
has a higher T g value, the net glass transition        
of miscible matrix is elevated, thus the 
molecular mobility of the drug is reduced. This 
is called the antiplasticization effect and can          
be   predicted by  the  Gordan  Taylor equation.  
Selection of high molecular weight carrier with 
high T g value and a high carrier:drug  ratio  can  
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further reduce the molecular mobility of the 
amorphous drug. For amorphous drugs, solid 
dispersions provide maximum stability benefit 
when the drug is molecularly dispersed in the 
carrier matrix. This also provides the solubility 
advantage as on dissolution of solid solution 
the drug is presented as a supersaturated 
solution or precipitated as fine colloidal 
particles or oil globule in submicron size. The 
commonly used antiplasticizers are the 
hydrophilic organic polymers such as 
polyvinylpyrrolidone, polyethylene glycol and 
various cellulose derivatives like hydroxypropyl-
methylcellulose, hydroxypropylcellulose etc. 
 
Interactions 
Specific reversible chemical interactions 
such as electrostatic bonds, vander waal forces 
and H-bonding between drug and carrier can 
limit the molecular mobility of drug in amorph-
ous state. The preferential interaction between 
drug and carrier can retard the self association 
of drug molecules thus inhibit the crystalliza-
tion process and contribute to the enhanced 
amorphous state solubility and stability. 
 
Pharmaceutical applications of 
amorphous solids  
Amorphous solids have a plethora of 
applications in the development of various 
dosage forms and it is evident from table I that 
the availability of market preparations of 
amorphous solids for clinical benefit. The 
importance of use of amorphous drugs in solid 
dosage forms are as follows. 
 
Dissolution enhancement 
They are used in the development of 
solid dispersions since rapid disintegration and 
dispersion occur from the dosage form. Onoue 
et al., (2009) developed novel amorphous solid 
dispersion respirable powder of CsA for 
pulmonary administration. In their findings, it 
is reported that the dissolution is improved 
after intratracheal administration with 71 and 
85% reduction of granulocyte recruitment in 
broncho alveolar lavage fluids and lung tissues, 
respectively, in rats (Onoue et al., 2009). 
 
Improvement of flow properties 
Spray dried dispersion powders can be 
developed with improved flow. Hirofumi 
Takeuchi et al., (2005) prepared amorphous 
solid dispersion particles of Indomethacin 
(IMC) with non-porous (Aerosil 200) and 
porous silica (Sylysia 350) by using spray-drying 
method. Dissolution property of IMC is 
remarkably improved by formulating the silica 
particles to the solid dispersion particles. The 
dissolution rate of IMC from solid dispersion 
with Sylysia 350 is rapid than that of Aerosil 
200 irrespective of IMC content and are stable 
at 40°C, 75% RH for 2 months (Hirofumi 
Takeuchi et al., 2005). 
 
Stability enhancement 
Hot melt extruded dispersion particles 
can be developed with improved 
compressibility and dissolution. Preparation of 
amorphous solid dispersions using hot-             
melt extrusion process of poorly water            
soluble compounds which degrade on melting 
remains a  challenge  due  to  exposure  to  high  
temperatures. Indrajit et al., (2011) developed a 
physically and chemically stable amorphous 
solid dispersion with enhanced dissolution of a 
poorly water-soluble compound, NVS981 
(using HPMC of three different grades) which 
is highly thermal sensitive and degrades upon 
melting at 165°C. 
Table I.  Marketed preparations of amorphous solids 
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Bioavailability enhancement 
Amorphous solid dispersions can be 
developed to improve exposure (increased 
bioavailability, more rapid onset, decrease 
dose), to support toxicology studies, as a 
clinical tool, to reduce variability and to 
decrease fed/fasted effects. Onoue et al., (2010) 
developed amorphous solid dispersion (SD) 
formulations of cyclosporine A (CsA) for 
improving the oral bioavailability of CsA. After 
the oral administration of HPC based SD, 
enhanced CsA exposure is observed with 
increase in Cmax and AUC of 5-fold. The 
amorphous SD approach using wet-               
milling technology is a promosing approach             
to enhan-ced bioavailability leading to an 
improved ther-apeutic potential of CsA. 
 
CONCLUSION 
The use of amorphous pharmaceutical 
materials is widely considered an effective way 
of improving favourable drug properties. 
Amorphous systems are an effective strategy in 
the pharmaceutical dosage form development 
and its importance is growing further due to 
the increasing number of insoluble molecules 
being pushed into the drug development 
pipeline. Physical instability due to devitrifica-
tion and chemical degradation are the major 
setbacks impeding their commercialize-tion.   
There are important considerations to make 
when formulating an amorphous substance. 
"An amorphous state is an interesting 
formulation opportunity for poorly soluble 
drugs. That means when solubility is very 
limited in the crystalline state. 
 
REFERENCES  
Adam, G., and Gibbs, J.H., 1965, On the 
temperature dependence of cooperative 
relaxation properties in glass-forming 
liquids, J. Chem, Phys. 43:139. 
Aguiar, A.J., Krc, J., Kinkel, A.W., and Samyn, 
J.C., 1967, Effect of polymorphism on 
absorption of chloramphenicol from 
chloramphenicol palmitate. J. Pharm. Sci. 
56:847-853. 
Ahlneck, C., and Zografi, G., 1990, The 
molecular basis of moisture effects on 
the physical and chemical stability of 
drugs in the solid state. Int. J. Pharm. 62: 
87-95. 
Alig, I., Braun, D., Lagendorf, R., Voigt, M., 
and Wendorff, J.H., 1997, Simultaneous 
ageing   and crystallization processes 
within the glassy state of a low molecular 
weight substance. J. Non-Cryst, Solids. 
221:261-264. 
Andronis, V., Yoshioka. M., and Zografi, G., 
1997, Effect of sorbed water on the 
crystallization of indomethacin from 
amorphous state. J. Pharm, Sci. 86(3): 
346- 351. 
Angell, C.A. 1996, Formation of glasses from 
liquids and biopolymers. J. Phys, Chem. 
100:13200-13212. 
Bhugra, C.,  Shmeis, R.., Krill, S.L., and Pikal, 
M.J., 2008, Prediction of onset of crystal-
zation from experimental relaxion times, 
II, Comparison between predicted and 
experimental onset times.  J. Pharm, Sci. 
97:455-472. 
Bhugra, C., Shmeis, R., Krill, S.L., and Pikal, 
M.J., 2006, Predictions of onset of 
crystal-lization in experimental relaxation 
times with comparison between 
predicted and experimental onset times. 
J. Pharm, Sci. 97:455-472. 
Brittain, H.G. 2002, Effects of mechanical 
processing on phase composition. J. 
Pharm. Sci. 91: 1573-1580. 
Byrn, Pfeiffer, Hoiberg, Ganey, and 
Poochician., 1995. Pharmaceutical solids: 
a strategic approach to regulatory 
considerations Pharm. Res. 12: 945. 
Carpenter, J.F., 1994, Interactions of stabilizers 
with proteins during freezing and drying, 
in Formulation and Delivery of Proteins and  
Peptides, ACS, Washington DC. pp. 134-
147. 
Carpentier, L., Decressain, R., Gusseme, A., 
Neves, C., dan Descamps, M., 2006,  
Molecular mobility in glass forming 
fananserine: A dielectric, NMR, and 
TMDSC investigation. Pharm. Res. 
23:798-805. 
Chawla, G., and Bansal, A.K., 2007, A 
comparative assessment of solubility 
advantage from glassy and    crystalline 
forms of a water insoluble drug. Eur, 
J.Pharm, Sci. 32: 45-57. 
Chiou, W.L., Riegelman S., 1970, Oral 
absorption of griseofulvin in dogs: 
Increased absorption via solid dispersion 
Gannu Praveen Kuma and Bakka Sravan Kumar 
Volume 23 Issue 2 (2012) 81 
in polyethylene glycol 6000. J. Pharm. Sci. 
59: 937-942. 
Crocker, L.S., and McCauley, J.A., 1997, 
Comparison of the crystallinity of 
imipenem samples by X ray diffraction 
of amorphous material. J. Pharm, Sci. 
84(2): 226-227. 
Crowe, J.H., Carpenter, J.F., dan Crowe, L.M. 
1998, The role of vitrification in 
anhydrobiosis. Annu. Rev. Physiol. 60:73-
103. 
Dmitri, V., and Louzguine-Luzgin., 2007,A  
glance on glass-transition phenomenon   
from the view point of devitrification. J. 
Alloys and Comp. 434-435  121-125. 
Elliot, S.R., Rao, N.R., and Thomas, J.M., 1986, 
The chemistry of the non-crystalline 
state. Chem. Int. Ed. Engl. 25: 31-46. 
Fang Z., Jaakko A., 2009, Influence of particle 
size and preparation methods on the  
physical and chemical stability of 
amorphous simvastatin. Eur. J.Pharm. and 
Biop. 71:64-70. 
Fulcher, G.S., 1925, Analysis of recent 
measurements of the viscosity of glasses. 
J. Am. Ceram. Soc. 8: 339-355. 
Garima C, Arvind B.K. 2009. Molecular 
Mobility and Physical Stability of  
Amorphous Irbesartan. Sci Pharm. 7:695-
709. 
Grant, D., Higuchi, T., 1990, Solubility Behaviour 
of Organic Compounds, 1st ed. John Wiley & 
Sons, New York. 
Gupta, P., and Arvind B. K., 2005,  
Devitrification of Amorphous Celecoxib. 
AAPS.  Pharm. Sci. Tech. 6(2) 
Gupta, P., Kakumanu, V.K., and Bansal, A.K., 
2004, Stability and solubility of 
celecoxib–PVP amorphous dispersions: 
A molecular perspective.  Pharm Res. 21: 
1762-1769. 
Hancock, B.C., Carlson, G.T., Ladipo, D.D., 
Langdon, B.A., and Mullarney, M.P., 
2002, Comparison of the mechanical 
properties of the crystalline and 
amorphous forms of a drug substance. 
Int, J. Pharm. 241(1): 73-85. 
Hancock, B.C., Dupuis, Y., and Thibert, R., 
1999, Determination of the viscosity of 
an amorphous drug   using thermo 
mecha-nical analysis (TMA). Pharm. Res. 
16:672-675. 
Hancock, B.C., Parks, M., 2000, What is the 
true solubility advantage for amorphous 
pharmaceuticals?. Pharm. Res. 17:397-404. 
Hancock, B.C., Shamblin, S.L., and Zografi, G., 
1995, Molecular mobility of amorphous 
pharmaceutical solids below their glass-
transition temperatures. Pharm. Res. 12: 
799-806. 
Hancock, B.C.,  Zografti, G., 1997,  Characte-
ristics and significance of the amorphous  
state in pharmaceutical systems. J. Pharm. 
Sci. 86:1-12 
Hancock, B.C. 2002, Disordered drug delivery: 
destiny, dynamics and the Deborah 
number. J. Pharm.  Pharmacol. 54 (6):737-
746 
Hilden, L.R., Morris, K.R. 2004, Physics of 
amorphous solids. J. Pharm, Sci. 93:3-12. 
Hodge, I.M., 1996, Strong and fragile liquids-A 
brief critique. J. Non-Cryst, Sol. 202:164-
172. 
Indrajit G., Jennifer Sr, Radha V., Marilyn A., 
Ronak V., Wei-Qin (Tony) T., and 
Sudha V., 2011, Comparison of HPMC 
based polymers performance as carriers 
for manufacture of solid dispersions 
using the melt extruder. Int. J. Phar. 
419:12-19 
Jacob, S., Nair, A. B., Patil, P. N., and Panda B. 
P., 2011, Solid state crystallinity, 
amorphous state, and its implications in 
the Pharmaceutical process., Ind. J. 
Pharm. Sci. Rres. 2(3):472-482. 
Jared, A., Baird, Lynne, S., and Taylor, 2011, 
Evaluation of Amorphous Solid Disper-
sion Properties using Thermal Analysis 
Techniques. S0169-409 X (11):00203-1. 
Jeong-Soo, Ki., 2008, Physico-chemical 
properties and oral bioavailability of 
amorphous atorvastatin hemi-calcium 
using spray-drying and SAS. Int. J. Pharm. 
359: 211-219. 
Kawakami, K., Pikal, M.J., 2005, Calorimetric 
investigation of the structural relaxation 
of   amorphous  materials: Evaluating 
validity of the methodologies. J. Pharm. 
Sci. 94: 948-965. 
Lian, Y., 2001, Amorphous pharmaceutical 
solids: preparation characterization and 
stabilization. Adv. Drug Del. Rev. 48: 27-
42. 
Current challenges of amorphous solids 
Volume 23 Issue 2 (2012) 82 
Longley, W., 1948. The Collected Works of J. 
Willard Gibbs. Yale University Press, New 
Haven.  
Marsac, P.J.,  Konno, H., Rumondor , A.C.F., 
and Taylor,  L.S., 2008, Recrystallization 
of nifedipine and felodipine from 
amorphous molecular level solid disper-
sions containing poly (vinylpyrrolidone) 
and sorbed water. Pharm, Res. 25:647-
656. 
Marsac, P.J.,  Konno,  H., and Taylor, L.S., 
2006,  A comparison of the physical 
stability of amorphous felodipine and 
nifedipine systems. Pharm. Res. 23: 2306-
2316. 
Morris, K.R., Griesser, U.J.,  Eckhardt, C.J., 
and Stowell, J.G., 2001,  Theoretical 
approaches to physical transformations 
of active pharmaceutical ingredients 
during manufacturing processes. Adv. 
Drug Deliv.Rev. 48:91-114. 
Nagapudi, K., and Jona, J., 2008, Amorphous 
Active Pharmaceutical Ingredients in 
preclinical Studies: Preparation, 
Characterization, and Formulation 
Current Bioactive Compounds. 4:213-
224 
Onoue, S., Sato, H., Kawabata, Y., Mizumoto, 
T., Hashimoto, N., Yamada., S., 2009, In 
vitro and in vivo characterization on   
amorphous solid dispersion of 
cyclosporine A for inhalation therapy. J. 
Contr. Rele. 138:16-23 
Onoue, S., Sato, H., Ogawa, K., Kawabata, Y., 
Mizumoto, T., Yuminoki, K., 
Hashimoto, N., and Yamada, S., 2010, 
Improved dissolution and pharmaco-
kinetic behavior of cyclosporine, A using 
high-energy amorphous solid dispersion 
approach. Int. J. Pharm. 399:94-101. 
Parks, G.S., Huffman, S.W., and Cattoir,  F.R., 
1928, Studies on glass II, The transition 
between the glassy   and liquid states in 
the case of glucose. J. Phys. Chem. 
32:1366-1379. 
Parks, G.S., Snyder, L.J., and Cattoir, F.R. 1934, 
Studies on glass XI, Some thermo 
dynamic relations of glassy and alpha-
crystalline glucose. J. Chem.  Phys. 2:595. 
Pikal, M., 1994, Freeze-drying of proteins: 
process, formulation and stability, in 
Formulation and Delivery of Proteins and 
peptides, by  Cleland, L.J., Langer, R., 
ACS,   Washington DC. pp 20-133. 
Pjohari, G., 2001, On extrapolating a 
supercooled liquid‟s excess entropy, the 
vibrational component, and reinter-
preting the configurational entropy 
theory. J. Phys, Chem. B105:3600-3604. 
Privalko, V.P., 1980, Excess entropies and 
related quantities in glass-forming 
liquids. J. Phys. Chem. 84:3307-3312. 
Richard Z., 1998,  The physics of amorphous 
solids 1st    Edition. Wiley, John & Sons, 
New York. 
Robertson, C.G., Santangelo, P.G., and Roland, 
C.M., 2000, Comparison of Glass 
Formation Kinetics and Segmental 
Relaxation in Polymers. J. of Non-Cryst. 
Solid. 275: 153-159. 
Rodrıguez-Hornedo, N., Murphy, D., 1999.  
Significance of controlling crystallization 
mechanisms and kinetics in pharma-
ceutical systems. J. Pharm. Sci. 88:651-
660. 
Saleki-Gerhardt, A.,  Stowell, J.G.,  Byrn, S.R.,  
and Zografi, G., 1995, Hydration and 
dehydration of crystalline and 
amorphous forms of raffinose. J. Pharm, 
Sci. 84:318-323 
Savolainen,  M.,  Kogermann, K., Heinz, A., 
Aaltonen, J.,  Peltonen, L., Strachan, C., 
and Liruusi, J.Y., 2009, Better 
understanding of dissolution behaviour 
of amorphous drugs by in situ solid-state 
analysis using Raman spectroscopy. Eur, 
J. Pharm. Biopharm. 71:7179 
Schmelzer, J., 2008, Crystal nucleation and 
growth in glass-forming melts: 
Experiment and theory. J. Non-Cryst. Sol. 
354:269-278. 
Shamblin, S.L., Tang, X., Chang, L., Hancock, 
B.C., and Jpikal, M., 1999, 
Characterization  of the time scales of 
molecular motion in pharmaceutically 
important glasses. J Phys  Chem.  B 103: 
4113-4121. 
Shmeis, R.A., Wang, Z., and Krill, S.L., 2004, A 
mechanistic investigation of an 
amorphous pharmaceutical and its solid 
dispersions, Part II: Molecular mobility 
and activation thermodynamic parame-
ters.  Pharm. Res. 21:2031-2039. 
Gannu Praveen Kuma and Bakka Sravan Kumar 
Volume 23 Issue 2 (2012) 83 
Sun, W.Q.,  Davidson, P., and Chan, H.S.O., 
1998, Protein stability in amorphous 
carbohydrate matrix:   Relavance to 
anhydrobio-sis,Biochim. Biophys. Acta. 
1425:245- 254. 
Takeuchi, H., Nagira, S., Yamamoto, H., and 
Kawashima, Y., 2005, Solid dispersion 
particles of amorphous in dome thacin 
with fine porous silica particles by using 
spray-drying method. Int. J. Phar. 
293:155-164. 
Tammann, G., Hesse, W., 1926. The 
dependency of viscosity on temperature 
in hypothermic liquids. Z. Anorg. Allg. 
Chem. 4:156. 
Tang, X.C., Pikal, M.J., and Taylor, L.J. 2002,  
A spectroscopic investigation of 
hydrogen bond patterns in crystalline 
and amorphous phases in dihydropy-
ridine calcium channel blockers. Pharm 
Res. 19:477-483 
Tombari, E., Ferrari, C., Johari, G.P., and 
Shanker, RM., 2008, Calorimetric 
relaxation in pharmaceutical molecular 
glasses and its utility in understanding 
their stability  against crystallization. J. 
Phys.  Chem. B. 112:10806-10814 
Vogel, H., 1921, The temperature dependence 
law of the viscosity of fluids. Physikal   
Zeitschr. 22:645-646 
Vyazovkin, S., Dranca, I., 2007, Effect of 
physical aging on nucleation of 
amorphous   indomethacin. J. Phys. Chem. 
B. 111: 7283-7287 
Vyazovkin,  S.,  Dranca, I., 2006,  Probing beta 
relaxation in pharmaceutically relevant 
glasses by using DSC. Pharm. Res. 23:422-
428. 
Weuts,  I.,  Kempen, D., and Six, K., 2003,  
Evaluation of different calorimetric 
methods to determine the glass 
transition temperature and molecular 
mobility below Tg for amorphous drugs. 
Int. J. Phar. 17-25. 
Williams,  G.,  Watts,  D.C., 1970, Non-
symmetrical dielectric relaxation be 
haviour arising from a simple empirical 
decay function. Trans. Faraday Soc. 66-80. 
Yoshioka, M., 1994, Crystallization of in 
domethacin from the amorphous state 
below and above its glass-transition 
temperature. J. Pharm. Sci.  83:1700-1705. 
Yoshioka, S., Aso, Y., 2007, Correlations 
between molecular mobility and 
chemical stability during storage of 
amorphous pharmaceuticals. J. Pharm, 
Sci. 96:960-981. 
Yoshioka, Y., Kojima, S., 2004, Molecular 
mobility-based estimation of the 
crystallization  rates of amorphous 
nifedipine and phenobarbital in poly 
(vinylpyrrolidone)  solid dispersions. J.  
Pharm. Sci. 93:384-391 . 
Yoshioka,  Y.S., Kojima, S., 2001, Explanation 
of the crystallization rate of amorphous 
nifedipine and phenobarbital from their 
molecular mobility as measured by 13C 
nuclear magnetic resonance relaxation 
time and the relaxation time obtained 
from the heating rate dependence of the 
glass transition temperature. J. Pharm. Sci. 
90:798-806. 
Yu, L., 2001, Amorphous pharmaceutical 
solids, preparation, characterization and 
stabilization. Adv. Drug Del. Rev. 48:27-
42. 
Zhou,  D., Zhang, G.G.Z., Law, D., Grant, 
D.L.W., and Schmitt, E.A., 2002,  
Physical stability of amorphous 
pharmaceuticals, importance of configu-
rationnally thermodynamic quantities  
and molecular mobility. J. Pharm. Sci. 
91:1863-1872. 
Zografi, G., and Hancock, B.C., 1994, Water 
solid interactions in pharmaceutical 
systems. Proceedings of the International 
Pharmaceutical Federation Conference. 
Tokyo, Japan. pp. 405-419 
 
